Energy Fuels Commencing Vanadium Production; Testing New Approaches to Mining in Tight Vanadium Market

LAKEWOOD, CO, Sept. 27, 2018 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that the Company expects to resume vanadium production at its 100% owned White Mesa Mill (the “Mill”) in mid-November 2018, producing significant quantities of salable V2O5 product by the end of…

CURE Pharmaceutical Secures Patent for Oral Thin Film Containing Bioactive Cannabinoid Molecules

CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, announced the allowance of an oral thin film patent (U.S. Patent No. 10092611), which covers the processing and integration of bioactive cannabinoid molecules into oral thin film dosage forms, such as CUREfilm(TM), the most advanced oral thin film on the market today. These molecules such…

Wealth Initiates New Geophysical Survey in Atacama Region

GlobeNewswire•September 17, 2018 VANCOUVER, British Columbia, Sept. 17, 2018 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQB: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces that following up on positive Transient Electromagnetic (“TEM”) and Magnetic Telluric (“MT”) geophysical survey results (see news release December 14, 2017), at the Company’s Atacama Project…

CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

GlobeNewswire•September 5, 2018 LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. Under the terms of the agreement, the cannabis company will have an exclusive…

Energy Fuels Significantly Strengthens Uranium Position in Wyoming through Acquisition of Royalties; Provides State with Notice of Intent to Repay Debt

LAKEWOOD, CO , Aug. 14, 2018 /CNW/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), a leading producer of uranium and vanadium in the United States , is pleased to announce that it has completed the previously announced acquisition from Excalibur Industries (“Excalibur”) of royalties on the Company’s 100%-owned…

Laguna Verde Update

GlobeNewswire•July 31, 2018 VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (WML.V) (WMLLF) (SSE:WMLCL) (EJZN.F), announces an operational update for the Laguna Verde Project (the “Project” or “Laguna Verde”). Preliminary Economic Assessment Wealth has commissioned several industry-leading consultants and advisors to produce a Preliminary Economic Assessment…

Atacama Project Update

GlobeNewswire•July 25, 2018 VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (WML.V) (WMLLF) (SSE:WMLCL) (EJZN.F), announces delays in its Atacama Project (the “Project”) drilling program. The Company mobilized and transported a sonic drill rig to the Project area this week, at which time local community representatives…

Ur-Energy and Energy Fuels Announce U.S. Department of Commerce Has Initiated Investigation into Effects of Uranium Imports on U.S. National Security

DENVER, July 18, 2018 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”) and Ur-Energy Inc. (NYSE American: URG; TSX: URE) (“Ur-Energy”) are pleased to announce that on July 18, 2018, the U.S. Department of Commerce (“DOC”) initiated an investigation into the effects of uranium imports on U.S. national security. This investigation was…

Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

Oxnard, CA – July xx, 2018 – CURE Pharmaceutical (OTCQB: CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq: TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of…